Wuhan, China · Founded 2017 · Privately Held (backing)
Developer of chemically-derived allogeneic cell therapies aims to provide first-in-class treatments for major degenerative diseases. iRegene is based in Wuhan, China and was founded in 2017. Its last reported valuation was $569 million in Apr 2025. It has raised $393 million.
Last reported valuation
$568.6M
Oct 2026
Priced at
—
Total raised
$392.8M
Last round
—
Team — not yet on record
No current team members for iRegene are on record yet. People surface from round filings, company disclosures, and coverage sessions.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of iRegene with a free account
·The complete investor list: 14 names
·Watch iRegene: the Monday email on marks, rounds and moves
